Current Issue
Volumes and Issues
For Authors
Manuscript Guidelines
Review Process
Conflict of Interest
Copyright
About the Journal
Editorial Board
Aim and Scope
Policy and Ethical Guidelines
Promotion of the Journal
Print-Version Subscription
Publisher and Contact Information
Contact Information
Sign in
ORIGINAL ARTICLE
ELECTROPHYSIOLOGICAL AND ELECTROACOUSTIC ASSESSMENT OF HEARING IN INDIVIDUALS WITH NEUROFIBROMATOSIS TYPE 1
1
Speech Therapy Department and Audiology, Federal University of São Paulo, Brazil
2
Department of Neurology and Neurosurgery, Support Group for Adolescents and Children with Cancer from Federal University of São Paulo, Brazil
A - Research concept and design; B - Collection and/or assembly of data; C - Data analysis and interpretation; D - Writing the article; E - Critical revision of the article; F - Final approval of article;
Publication date: 2021-03-31
Corresponding author
Raquel Caroline Ferreira Lopes Fontanelli
Speech Therapy Department and Audiology, Federal University of São Paulo, Rua Botucatu, 802, 04023-062, São Paulo, Brazil
Speech Therapy Department and Audiology, Federal University of São Paulo, Rua Botucatu, 802, 04023-062, São Paulo, Brazil
J Hear Sci 2021;11(1):46-53
KEYWORDS
brain stemotoacoustic emissionshearing disordersauditory pathwaysneurofibromatosis type 1hearing tests
TOPICS
ABSTRACT
Background:
Type 1 neurofibromatosis occurs in 1 in every 3,000 individuals, representing 90% of cases of neurofibromatosis. Hearing impairments are not commonly described as an alteration resulting from the pathology; however, sensorineural hearing losses with retrocochlear characteristics may occur as a result of the presence of acoustic neurinomas.
Objectives:
To assess the electrophysiological and electroacoustic hearing characteristics of individuals with neurofibromatosis type 1.
Material and methods:
We assessed 15 patients, 10 females and 5 males, aged between 9 and 31 years, using the following procedures: pure tone audiometry, transient evoked otoacoustic emissions, contralateral suppression of otoacoustic emissions, and brainstem auditory evoked potentials.
Results:
All individuals presented auditory thresholds within normal limits. The mean amplitude of the general responses of otoacoustic emissions in the right and left ears were 11.8 and 12.8 dB, respectively; the suppression effect of otoacoustic emissions was present in 73.3% for the right ear and 66.7% for the left. For brainstem auditory evoked potentials, we obtained mean wave latencies for the right and left ears respectively of wave I: 1.83 and 1.80 ms, III: 4.08 and 4.15 ms, and V: 5.96 and 6.09 ms.
Conclusions:
Individuals with neurofibromatosis type 1 present auditory thresholds within normal limits, present transient otoacoustic emissions, the nonsystematic presence of the suppression effect of otoacoustic emissions and prolonged latencies in brainstem auditory evoked potentials.
Type 1 neurofibromatosis occurs in 1 in every 3,000 individuals, representing 90% of cases of neurofibromatosis. Hearing impairments are not commonly described as an alteration resulting from the pathology; however, sensorineural hearing losses with retrocochlear characteristics may occur as a result of the presence of acoustic neurinomas.
Objectives:
To assess the electrophysiological and electroacoustic hearing characteristics of individuals with neurofibromatosis type 1.
Material and methods:
We assessed 15 patients, 10 females and 5 males, aged between 9 and 31 years, using the following procedures: pure tone audiometry, transient evoked otoacoustic emissions, contralateral suppression of otoacoustic emissions, and brainstem auditory evoked potentials.
Results:
All individuals presented auditory thresholds within normal limits. The mean amplitude of the general responses of otoacoustic emissions in the right and left ears were 11.8 and 12.8 dB, respectively; the suppression effect of otoacoustic emissions was present in 73.3% for the right ear and 66.7% for the left. For brainstem auditory evoked potentials, we obtained mean wave latencies for the right and left ears respectively of wave I: 1.83 and 1.80 ms, III: 4.08 and 4.15 ms, and V: 5.96 and 6.09 ms.
Conclusions:
Individuals with neurofibromatosis type 1 present auditory thresholds within normal limits, present transient otoacoustic emissions, the nonsystematic presence of the suppression effect of otoacoustic emissions and prolonged latencies in brainstem auditory evoked potentials.
REFERENCES (47)
1.
Miyawaki T, Billings B, Har-Shai Y, et al. Multicenter study of wound healing in neurofibromatosis and neurofibroma. J Craniofac Surg, 2007 Sep; 18(5): 1008–11.
3.
Ruggieri M, Huson SM. The neurofibromatosis: a overview. Ital J Neurol Sci, 1999; 20: 89–108.
4.
Mariaud-Schmidt RP, Rosales-Quintana S, Bitar E, et al. Hamartoma involving the pseudarthrosis site in patients with neurofibromatosis type 1. Pediatric Dev Pathol, 2005; 8: 190–6.
5.
Fortman BF, Kuszyk BS, Urban BA, Fishman EK. Neurofibromatosis type 1: a diagnostic mimicker at CT1. Radiographics, 2001 May-Jun; 21(3): 601–12.
6.
Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1728 patients. Am J Med Genet, 1997; 70: 138–43.
7.
Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol, 2005 Jan; 26(1): 93–7.
8.
Matlick, D. Clinical review: acoustic neuroma. Cinahl Rehabilitation Guide by EBSCO hosting. Ipswich, Massachusetts, October 10, 2008.
9.
White AK, Smith RJH, Bigler CR, Brooke WF, Schauer, PR. Head and neck manifestation of neurofibromatosis. Laryngoscope, 1986; 96: 732–7.
10.
Pikus AT. Pediatric audiologic profile in type 1 and type 2 neurofibromatosis. J Am Acad Audiol, 1995; 6(1): 54–62.
11.
Lustig LR, Jackler RK. Neurofibromatosis type I involving the external auditory canal. Otolaryngol Head Neck Surg, 1996; 114(2): 299–307.
12.
Barcelos-Corse LFD. Audiologic phenotype in individuals with neurofibromatosis type 1 [thesis]. Towson: Towson University; 2013.
13.
Jewett DL, Romano MN, Williston JS. Human auditory evoked potentials: possible brain stem components detected on the scalp. Science, 1970 Mar 13; 167(3924): 1517–8.
14.
Sousa LCA, Piza MRT, Alvarenga KF, Cóser PL. Eletrofisiologia da Audição e Emissões Otoacústicas: Princípios e Aplicações Clínicas. Ribeirão Preto: Editora Novo Conceito, 2010: 49–130.
15.
Liberman MC, Kujawa SG. The olivocochlear system and protection from acoustic injury: acute and chronic effect. In: Berlin CI. The Efferent Auditory System: Basic science and clinical applications. San Diego: Singular, 1999. p. 1–27.
16.
Hochman B, Nahas FX, Oliveira Filho RS, Ferreira LM. Desenhos de pesquisa. Acta Cirúrgica Brasileira. 2005; 20(Supl. 2): 2–9.
17.
Jerger S, Jerger J. Alterações auditivas: um manual para avaliação clínica. Atheneu: São Paulo; 1989. p. 102.
18.
Gattaz G, Ruggicri M, Bogar P. Evoked otoacoustic emissions study in normal hearing young adults. Brazilian Journal of Otorhinolaryngology, 1994; 60(1): 15–8.
19.
Kemp DT, Ryan S, Bray P. A guide to the effective use of otoacoustic emissions. Ear Hear, 1990 Apr; 11(2): 93–105.
20.
Hill JC, Pracher DK, Luxon LM. Evidence for efferent effects on auditory efferent activity, and their functional relevance. Clin Otolaryngol, 1997; 22(5): 394–402.
21.
Collet L, Veuillet E, Bene J, Morgon A. Effects of contralateral white noise on click-evoked emissions in normal and sensorineural ears: towards an exploration of the medial olivocochlear system. Audiology, 1992; 31(1): 1–7.
22.
Matas CG. Audiometria de tronco cerebral. In: Carvallo RMM. Fonoaudiologia: informação para a formação – procedimento em Audiologia. São Paulo: Guanabara Koogan; 2003, 43–56.
23.
Matas CG, Hataiama NM, Gonçalves IC. Estabilidade dos potenciais evocados auditivos em indivíduos adultos com audiçã o normal. Rev Soc Bras Fonoaudiol, 2011; 16(1): 37–41.
24.
Billingsley RL, Jackson EF, Slopis JM, Swank PR, Mahankali S, Moore BD. Functional magnetic resonance imaging of phonologic processing in neurofibromatosis 1. J Child Neurol, 2003; 18(11): 731–40.
25.
Billingsley RL, Jackson EF, Slopis JM, Swank PR, Mahankali S, Moore BD. Functional MRI of visual–spatial processing in neurofibromatosis, type I. Neuropsychologia, 2004; 42(3): 395–404.
26.
Souza JF, Toledo LL, Ferreira MCM, Rodrigues LOC, Rezende NA. Neurofibromatose Tipo 1: mais comum e grave do que se imagina. Rev Assoc Med Bras, 2009; 55(4): 394–9.
27.
Lorenzo J, Barton B, Arnold SS, North KN. Cognitive features that distinguish preschool-age children with neurofibromatosis type 1 from their peers: a matched case–control study. J Pediatrics, 2013; 163(5): 1479–83.
28.
Batista PB, Goloni-Bertolo EM, Souza-Costa D, et al. Neurofibromatosis: part 1 – diagnosis and differential diagnosis. Arq Neuropsiquiatr, 2014; 72(3): 241–50.
29.
Batista PB, Bertollo EMG, Costa DS, et al. Neurofibromatosis: part 2 – clinical management. Arq Neuropsiquiatr, 2015; 73(6): 531–43.
30.
Remigereau C, Roy A, Costini O, Barbarot S, Bru M, Gall DL. Praxis skills and executive function in children with neurofibromatosis type 1. Appl Neuropsychol Child, 2018 Jul-Sep; 7(3): 224–34.
31.
Lee MJ, Stephenson DA. Recent developments in neurofibromatosis type 1. Curr Opin Neurol, 2007; 20: 135–41.
32.
Ruggieri M, Upadhyaya M, Di Rocco C, et al. Neurofibromatosis type 1 and related disorders. In: Ruggieri M, Castroviejo IP, Di Rocco C. Neurocutaneous Disorders: Phakomatoses & Hamartoneoplastic Syndromes. Germany: Springer; 2008. 51–151.
33.
Cosyns M, Vandeweghe L, Mortier G, Janssens S, Van Borsel J. Speech disorders in neurofibromatosis type 1: a sample survey. Intl J Lang Commun Disord, 2010; 45(5): 600–7.
34.
Probst R. Otoacoustic emissions: an overview. Adv Otorhinolaryngol, 1990; 44: 1–91.
35.
Sone M, Katayama N, Otake N, Sato E, Fujimoto Y, Ito M, Nakashima T. Characterizing the auditory changes in tumor metastasis to the bilateral internal auditory canals. J Clin Neurosci, 2007 May; 14(5): 470–3.
36.
Rabinovich K. Estudo do efeito de supressão nas emissões otoacústicas evocadas transientes em indivíduos com audição normal e em portadores de esclerose múltipla. [Dissertation] São Paulo (SP): Universidade Federal de São Paulo; 1999.
37.
Liang F, Liu C, Liu B. [Otoacoustic emission and auditory efferent function testing in normal subjects and patients with sensorineural hearing loss]. Zhonghua Yi Xue Za Zhi, 1996 Oct; 76(10): 763–6. [Article in Chinese].
38.
Pialarissi PR, Rapoport PB, Gattaz G. Estudo da supressão dasemissões otoacústicas com a utilização de estímulos sonoros contralateraisem indivíduos de audição normal e em pacientes comdoenças retrococleares. Rev Bras Otorrinolaringol, 2000; 6(66):604–11.
39.
Sanches SGG, Carvallo RMM. Contralateral suppression of transientevoked otoacoustic in children with auditory processing disorders. Audiol Neurotol, 2006; 11: 366–72.
40.
Ardern-Holmes SL, North KN. Therapeutics for childhood neurofibromatosistype 1 and type 2. Curr Treat Options Neurol, 2011; 13(6): 529–43.
41.
Batista PB, Silva CM, Valentim HO, Rodrigues LOC, Rezende NA. Avaliação do processamento auditivo na Neurofibromatose tipo 1. Rev Soc Bras Fonoaudiol, 2010; 15(4): 604–8.
42.
Batista PB. Avaliação do processamento auditivo e da linguagem em pacientes com neurofibromatose tipo 1 [Dissertation]. Belo Horizonte: Universidade Federal de Minas Gerais; 2011.
43.
Batista PB, Lemos SMA, Rodrigues LOC, Rezende NA. Auditory temporal processing deficit and language disorders in patients with neurofibromatosis type 1. J Commun Disord, 2014; 48: 18–26.
44.
Khalfa S, Morlet T, Micheyl C, Morgon A. Evidence of peripheral hearing asymmetry in humans: clinical implications. Acta Otolaryngol, 1997; 117: 192–6.
45.
Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet, 2007; 44: 81–8.
46.
Pensak ML, Keith RW, Dignan PS, Stowens DW, Towbin RB, Katbamna B. Neuroaudiologic abnormalities in patients with type 1 neurofibromatosis. Laryngoscope, 1989; 99(7 Pt 1): 702–6.
47.
Ardern-Holmes SL, North KN. Therapeutics for childhood neurofibromatosis type 1 and type 2. Curr Treat Options Neurol, 2011; 13(6): 529–43.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
